Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial
出版年份 2023 全文链接
标题
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial
作者
关键词
-
出版物
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2023-08-23
DOI
10.1093/ndt/gfad183
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
- (2023) Hiddo J L Heerspink et al. LANCET
- Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure
- (2022) J. David Smeijer et al. JACC-Heart Failure
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
- (2022) Peter Rossing et al. KIDNEY INTERNATIONAL
- Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
- (2022) Markus P Schlaich et al. LANCET
- Adverse outcomes associated with rapid linear and non-linear patterns of chronic kidney disease progression
- (2021) Ibrahim Ali et al. BMC Nephrology
- Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
- (2021) Hiddo J L Heerspink et al. EUROPEAN HEART JOURNAL
- Bioimpedance Spectroscopy: Basics and Applications
- (2021) Daniil D. Stupin et al. ACS Biomaterials-Science & Engineering
- Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial
- (2021) Hiddo Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives
- (2021) Marc Evans et al. ADVANCES IN THERAPY
- Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
- (2021) Niels Jongs et al. Lancet Diabetes & Endocrinology
- Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response
- (2020) Gustaf J. Wellhagen et al. PHARMACEUTICAL RESEARCH
- Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial
- (2020) Megumi Oshima et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
- (2020) David C Wheeler et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
- (2020) Volker Vallon et al. Annual Review of Physiology
- Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
- (2020) Rosalie A. Scholtes et al. DIABETES CARE
- Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
- (2020) Jeroen V. Koomen et al. DIABETES OBESITY & METABOLISM
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction
- (2020) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status
- (2019) Craig J. Currie et al. PLoS One
- Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy
- (2018) Chih-Wei Lin et al. CLINICAL THERAPEUTICS
- Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight
- (2018) Jeroen V. Koomen et al. DIABETES OBESITY & METABOLISM
- Baseline characteristics and enrichment results from the SONAR trial
- (2018) Hiddo J.L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Synergistic effect of renalase and chronic kidney disease on endothelin-1 in patients with coronary artery disease ‒ a cross-sectional study
- (2018) Yu-Hsuan Li et al. Scientific Reports
- Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016
- (2018) Yan Xie et al. KIDNEY INTERNATIONAL
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis
- (2014) Agata Kowalczyk et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist
- (2014) J. Hoekman et al. Clinical Journal of the American Society of Nephrology
- The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
- (2014) D. de Zeeuw et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer
- (2013) K Miller et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Avosentan for Overt Diabetic Nephropathy
- (2010) J. F.E. Mann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
- (2009) R. R. Wenzel et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now